Company intelligence / Profile preview

Upstream Biotechnology

USA

Ownership: Private
Development stage: Preclinical

Overview

Upstream Biotechnology has developed the SwitchBlade™ platform to engineer broad-spectrum disease resistance into major crops. The technology has demonstrated efficacy against multiple devastating crop diseases across corn, citrus, tomato, soybean, and rice. No commercial launch or regulatory approval yet reported.[1][3]

Therapeutic areas: OtherInfectious Diseases
Modalities: Genetic traits for crop disease resistance (e.g., engineered plant immunity)
Industry: Agriculture & AgTech

Drug pipeline

1 asset

SwitchBlade

Pre-clinical

Indications: Plant diseases

Beyond the preview

Go deeper on Upstream Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Upstream Biotechnology.

Explore the full profile